MA29366B1 - Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure - Google Patents

Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure

Info

Publication number
MA29366B1
MA29366B1 MA30069A MA30069A MA29366B1 MA 29366 B1 MA29366 B1 MA 29366B1 MA 30069 A MA30069 A MA 30069A MA 30069 A MA30069 A MA 30069A MA 29366 B1 MA29366 B1 MA 29366B1
Authority
MA
Morocco
Prior art keywords
therapy
reacted
autoimmune disease
anterior
patients
Prior art date
Application number
MA30069A
Other languages
English (en)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA29366B1 publication Critical patent/MA29366B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UNE THÉRAPIE FAISANT APPEL À DES ANTAGONISTES ANGIOGÉNIQUES, PAR EXEMPLE DES ANTICORPS ANTI-VEGF. PLUS PRÉCISÉMENT, L'INVENTION CONCERNE L'UTILISATION DE CES ANTAGONISTES POUR TRAITER UNE MALADIE AUTO-IMMUNE CHEZ UN PATIENT QUI N'A PAS RÉAGI UN TRAITEMENT ANTÉRIEUR, PAR EXEMPLE UN TRAITEMENT FAISANT APPEL À DES DMARD OU À DES INHIBITEURS DE TNF$G(A).
MA30069A 2004-12-17 2007-07-12 Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure MA29366B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
MA29366B1 true MA29366B1 (fr) 2008-04-01

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30069A MA29366B1 (fr) 2004-12-17 2007-07-12 Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure

Country Status (23)

Country Link
US (2) US20060134111A1 (fr)
EP (1) EP1824885A1 (fr)
JP (1) JP2008524241A (fr)
KR (1) KR20070086218A (fr)
CN (1) CN101120020A (fr)
AR (1) AR052056A1 (fr)
AU (1) AU2005316403A1 (fr)
BR (1) BRPI0518105A (fr)
CA (1) CA2587932A1 (fr)
CR (1) CR9181A (fr)
IL (1) IL183347A0 (fr)
MA (1) MA29366B1 (fr)
MX (1) MX2007007165A (fr)
NO (1) NO20073651L (fr)
NZ (1) NZ555286A (fr)
PE (1) PE20061075A1 (fr)
RU (1) RU2007126970A (fr)
SG (1) SG158089A1 (fr)
SV (1) SV2006002342A (fr)
TN (1) TNSN07191A1 (fr)
TW (1) TW200634026A (fr)
WO (1) WO2006066086A1 (fr)
ZA (1) ZA200704898B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067796A1 (fr) 1999-05-07 2000-11-16 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (fr) * 2006-09-13 2008-03-20 Novartis Ag Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2727996A1 (fr) * 2008-11-06 2014-05-07 The Johns-Hopkins University Traitement des inflammations chroniques des voies respiratoires avec des inhibiteurs de NP1
EP3255060A1 (fr) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
EP2706358A3 (fr) * 2008-12-23 2014-05-07 Merck Patent GmbH Biomarqueurs pour inhibiteurs présentant une activité anti-angiogénique
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
EP3327032A1 (fr) 2010-08-06 2018-05-30 Genzyme Corporation Compositions antagonistes de vegf et leurs utilisations
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
KR20160146747A (ko) * 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
ES2622983T3 (es) * 2015-02-11 2017-07-10 Deutsches Krebsforschungszentrum Terapia contra el cáncer con un parvovirus combinado con bevacizumab
WO2019173692A2 (fr) 2018-03-09 2019-09-12 Agenus Inc. Anticorps anti-cd73 et leurs procédés d'utilisation
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
US20060134111A1 (en) 2006-06-22
CA2587932A1 (fr) 2006-06-22
RU2007126970A (ru) 2009-01-27
NZ555286A (en) 2010-04-30
MX2007007165A (es) 2007-08-14
TW200634026A (en) 2006-10-01
ZA200704898B (en) 2009-03-25
PE20061075A1 (es) 2006-11-15
AU2005316403A1 (en) 2006-06-22
KR20070086218A (ko) 2007-08-27
CN101120020A (zh) 2008-02-06
BRPI0518105A (pt) 2008-11-04
US20080214789A1 (en) 2008-09-04
IL183347A0 (en) 2007-09-20
EP1824885A1 (fr) 2007-08-29
AR052056A1 (es) 2007-02-28
WO2006066086A1 (fr) 2006-06-22
SV2006002342A (es) 2006-06-01
NO20073651L (no) 2007-09-10
SG158089A1 (en) 2010-01-29
JP2008524241A (ja) 2008-07-10
CR9181A (es) 2008-07-31
TNSN07191A1 (en) 2008-11-21

Similar Documents

Publication Publication Date Title
MA29366B1 (fr) Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
MA31668B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
WO2001054681A8 (fr) Composition anti-stress
MA30252B1 (fr) Vaccin therapeutique
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
EP1385508A4 (fr) Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
EP1401498A4 (fr) Anticorps anti-ngf pour le traitement de divers troubles
EP1545613A4 (fr) Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MA27863A1 (fr) Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
MA27592A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA60154A1 (fr) Inhibiteurs de line-1 pour traiter une maladie
TW200500079A (en) Compositions and methods for treating coronavirus infection and sars
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif